For example, knocking out of the Fc Fragment of IgG receptor isoforms (FCGR1A, FCGR2B, and FCGR3a)– which are required for the manifestation of antibody-dependent cellular cytotoxicity and anti-angiogenic activity of bevacizumab [33], which targets the vascular endothelial growth factor receptor (VEGFR) in ovarian, intestinal, and kidney cancers, did not influence the cancer cell fitness (Figure 2C). This evidence concerns the gene KDR and cancer.